Comparator supply for NCT04680052
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
Sponsor: Incyte Corporation (INDUSTRY). Phase: PHASE3. Status: Active Not Recruiting. Countries: United States, Australia, Austria, Belgium, Canada, Czechia, Denmark, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Japan, Netherlands, Norway, Poland, Russia, South Korea, Spain, Sweden, Switzerland, Taiwan, Turkey (Türkiye), Ukraine, United Kingdom. Last update posted 2026-09-04.
Registry record: https://clinicaltrials.gov/study/NCT04680052.
Canadian-labelled lenalidomide
42 marketed Canadian product(s) from 7 manufacturer(s) contain lenalidomide. Available strengths: 10 MG, 15 MG, 2.5 MG, 20 MG, 25 MG, 5 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled rituximab
7 marketed Canadian product(s) from 4 manufacturer(s) contain rituximab. Available strengths: 10 MG, 100 MG / 10 ML, 1400 MG / 11.7 ML, 1600 MG / 13.4 ML, 500 MG / 50 ML. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled tafasitamab
1 marketed Canadian product(s) from 1 manufacturer(s) contain tafasitamab. Available strengths: 200 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
What we supply
- Canadian-labelled comparator sourced through licensed Canadian supply
- Certificate of Analysis for every batch
- Batch number and expiry documentation, with retained records
- Blinding-ready packaging and over-encapsulation on request
- 2–8 °C validated cold chain with temperature logging where required
- Health Canada Drug Establishment Licence #3-002896
Frequently asked questions
Can Nexara supply Canadian-labelled lenalidomide as a trial comparator?
Yes. We source Canadian-marketed lenalidomide under Health Canada Drug Establishment Licence #3-002896 and ship it with Certificate of Analysis, batch number and expiry documentation for use as a comparator or rescue supply in NCT04680052.
What documentation comes with each shipment?
Certificate of Analysis, manufacturer batch and expiry records, chain-of-custody documentation from the Canadian supply chain, and temperature records where cold chain applies. Blinding-ready packaging is available on request.
How long does comparator supply take?
Quotes are returned within one business day. Lead time depends on the presentation and the destination country's import route — typically 10 to 21 days once the importer's licence and any notification are in place.
Request comparator quote
Request comparator quote or call +1-431-588-9055.